# Replimune Group, Inc. (REPL)

> Replimune Group, Inc. (REPL) trades at $19.72 (+0.13%) as of 6:21:42 AM EST on Nov 19, 2026, +73.47% over the past month. Market cap is $1.88B, with 8.3 days to cover in short interest.

Canonical: https://massive.com/quote/repl
Data as of: 2026-11-19T11:21:42.604Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$19.72** +0.03 (+0.13%)
As of 6:21:42 AM EST on Nov 19, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Replimune Group, Inc. (REPL) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.61% |
| 1W | -9.04% |
| 1M | +73.47% |
| YTD | +103.81% |
| 1Y | +119.87% |
| 52-wk range | $1.50 – $23.54 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for REPL: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $19.33 – $20.12 |
| Open | $19.63 |
| Prev close | $19.69 |
| Volume | 2.13M |
| Market cap | $1.88B |
| Shares out | 94.8M |

## Valuation and profitability ratios

Valuation and profitability ratios for Replimune Group, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 9.17 |
| P/FCF | — |
| ROE | -132.4% |
| ROA | -72.5% |
| Debt/Equity | 0.61 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Replimune Group, Inc. (REPL) insider trading](https://massive.com/quote/repl/insider-trading.md): open-market Form 4 buys and sells by Replimune Group, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Replimune Group, Inc. has disclosed to the SEC on Form 8-K.

- Oct 28, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On October 28, 2026, Replimune Group, Inc. issued a news release announcing its financial results for the second fiscal quarter ended September 30, 2026 and certain corporate updates.”
- Sep 16, 2026 · Annual meeting results
  “The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below. ... Proposal No. 1 ... was ratified; Proposal No. 2 ... was approved on a non-binding advisory basis; \[and\] Proposal No. 3 ... was approved by the Company's stockholders.”
- Aug 10, 2026 · Public offering
  “On August 9, 2026, Replimune Group, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. relating to the issuance and sale of an aggregate of 9,701,490 shares of the Company's common stock (the "Shares") and pre-funded warrants to purchase 2,736,340 shares of the Company's common stock (the "Pre-Funded Warrants"). The Shares will be sold at the offering price of $12.06 per share and the Pre-Funded Warrants will be sold at an offering price of $12.0599 per Pre-Funded Warrant.”
- Aug 7, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “the U.S. Food and Drug Administration has granted accelerated approval for TUDRIQEVTM (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen.”
- Jul 31, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “The U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee met to discuss the Company's Biologics License Application ("BLA") resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful.”

## Dividend history and stock splits

Replimune Group, Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 15-for-1 · Dec 1, 2010

## REPL short interest

How heavily REPL is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.3 |
| Short interest | 24.61M |
| Avg volume | 2.96M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## REPL news

The latest news and headlines about Replimune Group, Inc. (REPL).

- [Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet](https://www.zacks.com/stock/news/3031805/wall-street-analysts-think-replimune-group-repl-could-surge-29-51-read-this-before-placing-a-bet?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3031805) · Zacks Investment Research · Nov 18, 2026 · positive sentiment
- [REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress](https://www.zacks.com/stock/news/3028784/repl-stock-up-80-in-a-month-on-tudriqev-launch-pipeline-progress?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-3028784) · Zacks Investment Research · Nov 12, 2026 · positive sentiment
- [Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade](https://www.zacks.com/stock/news/3020609/wall-street-analysts-believe-replimune-group-repl-could-rally-26-8-here-s-is-how-to-trade?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3020609) · Zacks Investment Research · Nov 2, 2026 · positive sentiment
- [Replimune: 3 Key Takeaways for Long-Term Investors](https://www.fool.com/earnings/takeaways/2026/10/28/replimune-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001) · The Motley Fool · Oct 28, 2026 · positive sentiment
- [Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors](https://www.globenewswire.com/news-release/2026/10/20/3384047/0/en/mestag-therapeutics-appoints-philip-astley-sparke-and-victor-sandor-m-d-c-m-to-its-board-of-directors.html) · GlobeNewswire Inc. · Oct 20, 2026 · positive sentiment

## About Replimune Group, Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 465 |
| Listed | Jul 20, 2018 |

[Company website](https://www.replimune.com)

## FAQ

### What is the Replimune Group, Inc. (REPL) stock price today?

Replimune Group, Inc. (REPL) is trading at $19.72 (+0.13% on the day) as of 6:21:42 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Replimune Group, Inc.?

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies.

### What is the short interest in REPL?

As of Oct 30, 2026, REPL has 24.61M shares short and 8.3 days to cover.

### What exchange is REPL listed on?

Replimune Group, Inc. (REPL) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time REPL quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=REPL`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Replimune Group, Inc. (REPL) insider trading](https://massive.com/quote/repl/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
